GlassScriptPhysician profile
Betsy L Null
NPI 1154445849
$4,164.16
in general payments reported to CMS, 2019-2025
35 companies · $986 in 2025
The $986 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $554 · 2023: $1,218 · 2024: $1,406 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,525 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,525.09 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $675.51 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $625.99 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $471.36 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $393.22 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $212.10 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $212.03 | 2022-2025 | |
| Abbvie INC. | $200.96 | 2022-2024 | |
| Amgen INC. | $160.37 | 2022-2025 | Evenity, Repatha, Otezla |
| Astellas Pharma US INC | $154.38 | 2023-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $131.66 | 2022-2025 | Breztri, Farxiga |
| Shield Therapeutics INC | $94.27 | 2024 | |
| Antares Pharma, INC. | $91.93 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.59 | 2022-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $82.77 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Halozyme INC | $68.87 | 2023 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betsy Null listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.